MCID: INV001
MIFTS: 48

Invasive Aspergillosis

Categories: Genetic diseases, Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Invasive Aspergillosis

MalaCards integrated aliases for Invasive Aspergillosis:

Name: Invasive Aspergillosis 12 15 71
Aspergillosis Invasive 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050073
UMLS 71 C0238013

Summaries for Invasive Aspergillosis

Disease Ontology : 12 An aspergillosis that is a serious fungal infection of the lung with pneumonia caused by Aspergillus, which spreads to other parts of the body through bloodstream in patients with acute leukemia and recipients of tissue transplants. Clinical symptoms include pulmonary nodules and hemorrhage.

MalaCards based summary : Invasive Aspergillosis, also known as aspergillosis invasive, is related to chronic granulomatous disease and acute graft versus host disease. An important gene associated with Invasive Aspergillosis is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Amphotericin B and Itraconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Related Diseases for Invasive Aspergillosis

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Invasive Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 558)
# Related Disease Score Top Affiliating Genes
1 chronic granulomatous disease 31.1 TLR5 IFNG CXCL8 CSF3
2 acute graft versus host disease 30.7 NOD2 IL10 IFNG CSF3
3 bronchopneumonia 30.7 TLR4 IL10 CXCL8
4 aspergillosis 30.6 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
5 candidiasis 30.5 TLR4 TLR2 MBL2 IL10 IFNG CXCL8
6 endocarditis 30.4 TLR6 TLR2 IL10 IFNG CXCL8
7 toxic shock syndrome 30.4 TLR4 TLR2 IL10 IFNG CXCL8
8 endophthalmitis 30.4 TLR2 PLG CXCL8
9 respiratory failure 30.3 SFTPD IL10 CXCL8 CXCL10
10 legionellosis 30.3 TLR5 TLR4 TLR2 CXCL8
11 allergic bronchopulmonary aspergillosis 30.3 SFTPD MBL2 IL10 IFNG FLNC
12 chronic graft versus host disease 30.3 IL10 IFNG
13 alcoholic hepatitis 30.3 TLR4 TLR2 IL10 CXCL8
14 immune deficiency disease 30.3 MBL2 IL10 IFNG CXCL10 CCR6
15 cryptococcosis 30.2 MBL2 IL10 IFNG CLEC7A CCR6
16 hyper ige recurrent infection syndrome 1 30.2 IL10 CLEC7A CCR6
17 autoimmune disease 30.1 MBL2 IL10 IFNG CXCL8 CCR6
18 cystic fibrosis 30.1 TLR4 SFTPD PLG MBL2 IL10 CXCL8
19 fusariosis 30.1 CYP51A1 CSF3
20 pulmonary alveolar proteinosis 30.1 SFTPD IL10 CXCL8
21 idiopathic interstitial pneumonia 30.1 SFTPD IFNG CXCL8 CCR6
22 pulmonary tuberculosis 30.1 TLR4 TLR2 MBL2 IL10 IFNG
23 optic neuritis 30.0 IL10 CXCL8 CXCL10
24 neuritis 30.0 IL10 IFNG CXCL8 CXCL10
25 mucormycosis 30.0 IFNG FLNC CYP51A1 CSF3 CLEC7A CCR6
26 pulmonary sarcoidosis 30.0 SFTPD IFNG CCR6
27 pleural disease 30.0 IFNG CXCL8 CCR6
28 conjunctivitis 30.0 PLG IL10 IFNG CXCL8
29 adult respiratory distress syndrome 30.0 SFTPD IL10 CXCL8 CSF3
30 appendicitis 29.9 TLR4 IL10 IFNG CXCL8 CSF3
31 esophageal candidiasis 29.9 FLNC CYP51A1 CCR6
32 peritonitis 29.9 TLR4 TLR2 IL10 IFNG CXCL8 CSF3
33 bronchitis 29.9 TLR4 TLR2 IL10 CXCL8 CXCL10
34 diarrhea 29.9 TLR4 IL10 IFNG CXCL8 CSF3
35 bronchiolitis obliterans 29.9 TLR4 SFTPD IL10 IFNG CXCL8
36 spondylitis 29.9 NOD2 IL10 IFNG CCR6
37 plasmodium falciparum malaria 29.8 IL10 IFNG HBB
38 myeloma, multiple 29.8 TLR4 IL10 IFNG CXCL8 CSF3 CCR6
39 pulmonary disease, chronic obstructive 29.8 TLR4 TLR2 SFTPD IL10 CXCL8 CXCL10
40 pyoderma 29.8 NOD2 CXCL8 CSF3 CCR6
41 pyoderma gangrenosum 29.8 NOD2 CXCL8 CSF3 CCR6
42 septic arthritis 29.8 TLR5 TLR4 TLR2 IFNG CXCL8
43 sarcoidosis 1 29.8 SFTPD NOD2 IFNG CXCL10 CCR6
44 vascular disease 29.7 TLR4 PLG IL10 IFNG CSF3
45 osteomyelitis 29.7 TLR4 TLR2 NOD2 IL10 IFNG CXCL8
46 pneumocystosis 29.5 SFTPD FLNC CSF3 CLEC7A CCR6 CABIN1
47 thrombocytopenia 29.5 TLR5 TLR4 TLR2 IL10 IFNG CXCL8
48 ulcerative colitis 29.5 TLR5 TLR4 NOD2 IL10 IFNG CXCL8
49 lung disease 29.4 TLR5 TLR4 TLR2 SFTPD MBL2 IL10
50 bacterial sepsis 29.4 TLR4 TLR2 TLR1 IL10 CXCL8 CCR6

Graphical network of the top 20 diseases related to Invasive Aspergillosis:



Diseases related to Invasive Aspergillosis

Symptoms & Phenotypes for Invasive Aspergillosis

GenomeRNAi Phenotypes related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCR6 CLEC7A CSF3 CXCL8 CYP51A1 FLNC

MGI Mouse Phenotypes related to Invasive Aspergillosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 CABIN1 CCR6 CLEC7A CSF3 CXCL10 IFNG
2 cardiovascular system MP:0005385 10.1 CCR6 CXCL10 CYP51A1 FLNC IFNG IL10
3 homeostasis/metabolism MP:0005376 10.1 CCR6 CLEC7A CXCL10 CYP51A1 FLNC IFNG
4 immune system MP:0005387 10.09 CABIN1 CCR6 CLEC7A CSF3 CXCL10 CYP51A1
5 digestive/alimentary MP:0005381 10.02 CLEC7A CYP51A1 IFNG IL10 NOD2 PLG
6 mortality/aging MP:0010768 9.77 CABIN1 CLEC7A CXCL10 CYP51A1 FLNC IFNG
7 respiratory system MP:0005388 9.28 CLEC7A FLNC IFNG IL10 PLG SFTPD

Drugs & Therapeutics for Invasive Aspergillosis

Drugs for Invasive Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
2
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5 Liposomal amphotericin B Phase 4
6 Liver Extracts Phase 4
7 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
8 Pharmaceutical Solutions Phase 4
9
Hydroxyitraconazole Phase 4
10 glucocorticoids Phase 4
11
Midazolam Approved, Illicit Phase 2, Phase 3 59467-70-8 4192
12
deoxycholic acid Approved Phase 3 83-44-3 222528
13
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
14
Pirfenidone Approved, Investigational Phase 2, Phase 3 53179-13-8 40632
15 Cholagogues and Choleretics Phase 3
16 Amphotericin B, deoxycholate drug combination Phase 3
17 Antirheumatic Agents Phase 2, Phase 3
18 Anti-Inflammatory Agents Phase 2, Phase 3
19 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
20 Analgesics, Non-Narcotic Phase 2, Phase 3
21 Analgesics Phase 2, Phase 3
22
Isavuconazole Approved, Investigational Phase 2 241479-67-4
23 Antiviral Agents Phase 2
24 interferons Phase 2
25 Interferon-gamma Phase 2
26
Rifampicin Approved Phase 1 13292-46-1 5458213 5381226
27 Anti-Anxiety Agents Phase 1
28 Tranquilizing Agents Phase 1
29 Neurotransmitter Agents Phase 1
30 Hypnotics and Sedatives Phase 1
31 Adjuvants, Anesthesia Phase 1
32 Anesthetics Phase 1
33 GABA Agents Phase 1
34 Anesthetics, General Phase 1
35 Psychotropic Drugs Phase 1
36 GABA Modulators Phase 1
37 Anesthetics, Intravenous Phase 1
38 Central Nervous System Depressants Phase 1
39
Chloramphenicol succinate Approved 3544-94-3
40
Chloramphenicol Approved, Vet_approved 56-75-7 298 5959
41
Caspofungin Approved 162808-62-0, 179463-17-3 468682 2826718
42 Fluorodeoxyglucose F18
43 Radiopharmaceuticals
44 Respiratory System Agents
45 Expectorants
46 Anti-Bacterial Agents

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
2 Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective,Open Cohort Study (VIA-COPD) Unknown status NCT02234739 Phase 4 Voriconazole
3 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
5 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
6 Pharmacokinetics of Voriconazole in Obese Subjects Completed NCT01030653 Phase 4 Voriconazole low dose;Voriconazole high dose
7 Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy Completed NCT01539330 Phase 4 Voriconazole
8 A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels Recruiting NCT03731169 Phase 4 Standard of Care
9 Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
10 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment) Terminated NCT02646774 Phase 4 Micafungin
11 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
12 A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
13 An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis. Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
14 A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. Completed NCT00412893 Phase 3 Isavuconazole;Voriconazole
15 A Multicentre Randomised Controlled Trial Comparing the Current Standard Diagnostic Strategy for Invasive Aspergillosis to the New Diagnostic Strategy for Invasive Aspergillosis in High-Risk Haematology Patients in Order to Determine Which Strategy Results in the Lower Rates of Use of Empiric Antifungal Therapy Completed NCT00163722 Phase 3
16 A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069) Completed NCT01782131 Phase 3 Posaconazole;Voriconazole
17 Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients Completed NCT00158730 Phase 3 AmBisome
18 An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
19 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
20 Using Serum Galactomannan Levels in a Prospective, Randomised, Non-blinded Trial to Guide Early Anti-fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis. Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
21 A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin;voriconazole
22 Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi Completed NCT00634049 Phase 3 isavuconazole
23 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001810 Phase 3 Voriconazole
24 Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) Completed NCT00177684 Phase 3 Amphotericin B
25 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Active, not recruiting NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
26 A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients Active, not recruiting NCT02262299 Phase 2, Phase 3 Pirfenidone;Placebo
27 A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients. Terminated NCT00836875 Phase 3 Voriconazole
28 A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years Withdrawn NCT01188759 Phase 3 Voriconazole;Anidulafungin;Voriconazole
29 Prophylaxis With Caspofungin for the Prevention of Invasive Fungal Infections in High-Risk Liver Transplant Recipients Unknown status NCT00333645 Phase 2 Caspofungin
30 A Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy of Caspofungin as Prophylactic Treatment of Invasive Fungal Infections in Patients With Acute Leukemia Undergoing Induction Chemotherapy Completed NCT00501098 Phase 2 Caspofungin
31 AMBINEB: Clinical Trial to Evaluate Tolerance and Safety of Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis in Patients With Acute Myeloid Leukemia and Allogeneic Haematopoietic Progenitor Cell Transplant (Alo-HPCT) Completed NCT00391014 Phase 2 liposomal Amphotericine B
32 A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia Completed NCT01615809 Phase 2 AMPHOTERICIN B
33 A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of MK0991 in Combination With Amphotericin B, Lipid Formulations of Amphotericin B, or Azoles in the Treatment of Invasive Aspergillus Infection in Adults Who Are Refractory to or Intolerant of Standard Therapy Completed NCT00076869 Phase 2 MK0991, caspofungin acetate;Comparator: amphotericin B;Comparator: lipid formulation of amphotericin B and/or azole
34 A Phase II Dose Escalation Study of Caspofungin in Patients With Invasive Aspergillosis Completed NCT00404092 Phase 2 caspofungin
35 An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis Completed NCT00036166 Phase 2 FK463
36 A Prospective, Randomized, Double-Blind, Multicenter Pilot Study Of The Safety And Efficacy Of Interferon Gamma- 1b (IFN-y 1b) Plus Voriconazole Versus Placebo Plus Voriconazole In The Treatment Of Invasive Aspergillosis And Other Filamentous Fungal Infections Completed NCT00059878 Phase 2 voriconazole
37 Pharmacokinetics of Micafungin (Mycamin ®) as Antifungal Prophylaxis Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease. Completed NCT02172768 Phase 2 micafungin
38 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
39 Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options Recruiting NCT03583164 Phase 2 F901318
40 A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 With Voriconazole in Patients With Invasive Pulmonary Aspergillosis Recruiting NCT03672292 Phase 2 SCY-078;Voriconazole
41 A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects Recruiting NCT03816176 Phase 2 Isavuconazonium sulfate;Isavuconazonium sulfate
42 A Phase II Study of Isavuconazole Prophylaxis in Adult Patients With AML/MDS and Neutropenia Active, not recruiting NCT03019939 Phase 2 Isavuconazole
43 Universal Posaconazole Prophylaxis Versus Pre-emptive Posaconazole Therapy for Fungal Infection Management Post-lung Transplantation Not yet recruiting NCT03561415 Phase 2
44 PIVOTAL: Pharmacological Individualisation of VOriconazole Therapy for AntifungaL Treatment Suspended NCT01887457 Phase 2 VFEND
45 A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients Terminated NCT03327727 Phase 2 Investigational Agent: VL-2397;Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
46 A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis Terminated NCT00376337 Phase 2 Micafungin;Systemic antifungal therapy
47 A Phase 2, Open-Label, Non-Comparative Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) as First-Line Therapy in the Treatment of Invasive Aspergillosis Terminated NCT00047827 Phase 2 Micafungin;Liposomal Amphotericin B
48 A Phase II Randomized, Double Blind, Placebo-controlled, Trial of Combination Antifungal Therapy (Voriconazole Plus Micafungin vs. Voriconazole Plus Placebo Equivalent) in the Treatment of Invasive Aspergillosis (IA) in Patients With Hematological Cancer Withdrawn NCT01207128 Phase 2 Voriconazole, micafungin
49 An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Intravenous and Oral F901318 (Combined With Caspofungin) for Antifungal Prophylaxis in Patients Undergoing Chemotherapy for Acute Myeloid Leukaemia Withdrawn NCT02856178 Phase 1, Phase 2 F901318;Caspofungin
50 Clinical Trials to Evaluate the Influence of CYP2C19 Genotype and Drug-drug Interactions on the Pharmacokinetics of Voriconazole in Healthy Korean Male Volunteers (Part B) Completed NCT01080651 Phase 1 Voriconazole

Search NIH Clinical Center for Invasive Aspergillosis

Genetic Tests for Invasive Aspergillosis

Anatomical Context for Invasive Aspergillosis

MalaCards organs/tissues related to Invasive Aspergillosis:

40
Lung, Testes, Liver, Myeloid, Bone, Bone Marrow, T Cells

Publications for Invasive Aspergillosis

Articles related to Invasive Aspergillosis:

(show top 50) (show all 4011)
# Title Authors PMID Year
1
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. 54 61
18946062 2008
2
Aspergillus fumigatus induces innate immune responses in alveolar macrophages through the MAPK pathway independently of TLR2 and TLR4. 54 61
16951362 2006
3
TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. 54 61
16461792 2005
4
A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy. 61
31879587 2020
5
Fungal Rhinosinusitis and Disseminated Invasive Aspergillosis in Cats. 61
31866094 2020
6
Necrotizing soft tissue invasive aspergillosis in a cancer patient treated with immunosupressants due to checkpoint inhibitor-induced hepatitis. 61
31705917 2020
7
Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood. 61
31372914 2020
8
Molecular Mechanisms of Conidial Germination in Aspergillus spp. 61
31801804 2020
9
Routine Comprehensive Aspergillus Screening of Bronchoalveolar Lavage Samples in Lung Transplant Recipients. 61
32017265 2020
10
A population-based analysis of attributable hospitalisation costs of invasive fungal diseases in haematological malignancy patients using data linkage of state-wide registry and costing databases: 2009-2015. 61
31715052 2020
11
Aspergillus flavus malignant external otitis in a diabetic patient: case report and literature review. 61
32036556 2020
12
Synergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms. 61
32028887 2020
13
Surgical resection for persistent localized pulmonary fungal infection prior to allogeneic hematopoietic stem cell transplantation: Analysis of six cases. 61
31735628 2020
14
The histone acetyltransferase GcnE regulates conidiation and biofilm formation in Aspergillus fumigatus. 61
31100153 2020
15
The Aspergillus fumigatus Phosphoproteome Reveals Roles of High-Osmolarity Glycerol Mitogen-Activated Protein Kinases in Promoting Cell Wall Damage and Caspofungin Tolerance. 61
32019798 2020
16
Performance of the AsperGenius® PCR assay for detecting azole resistant Aspergillus fumigatus in BAL fluids from allogeneic HSCT recipients: A prospective cohort study from Essen, West Germany. 61
31111913 2020
17
Reducing Aspergillus fumigatus Virulence through Targeted Dysregulation of the Conidiation Pathway. 61
32019801 2020
18
High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. 61
31660650 2020
19
Invasive Pulmonary Aspergillosis. 61
32000286 2020
20
Aspergillus fumigatus Cell Wall Promotes Apical Airway Epithelial Recruitment of Human Neutrophils. 61
31767773 2020
21
Molecular Detection of Aspergillus: Application of a Real-Time PCR Multiplex Assay in Tissue Samples. 61
31936735 2020
22
Evaluation of Commercially Available Real-Time Polymerase Chain Reaction Assays for the Diagnosis of Invasive Aspergillosis in Patients with Haematological Malignancies. 61
31950340 2020
23
Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus. 61
31171644 2020
24
Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports. 61
31912423 2020
25
Melanin and pyomelanin in Aspergillus fumigatus: from its genetics to host interaction. 61
31020477 2020
26
Mutation in cyp51A and high expression of efflux pump gene of Aspergillus fumigatus induced by propiconazole in liquid medium and soil. 61
31662261 2020
27
Detecting Azole-Antifungal Resistance in Aspergillus fumigatus by Pyrosequencing. 61
31936898 2020
28
The Transcriptional Regulator HbxA Governs Development, Secondary Metabolism, and Virulence in Aspergillus fumigatus. 61
31757831 2020
29
Azole resistance mechanisms in Aspergillus: update and recent advances. 61
31542320 2020
30
Characterization of Aspergillus fumigatus mitochondrial acetyl-CoA acetyltransferase as an antifungal target. 61
32005728 2020
31
Chitin deacetylases Cod4 and Cod7 are involved in polar growth of Aspergillus fumigatus. 61
31602821 2020
32
Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient. 61
31925638 2020
33
Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia. 61
31787568 2020
34
Polymorphisms within the ARNT2 and CX3CR1 genes are associated with the risk of developing invasive aspergillosis. 61
31964743 2020
35
A comparison of histomorphologic diagnosis with culture- and immunohistochemistry-based diagnosis of invasive aspergillosis and mucormycosis. 61
31973617 2020
36
Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis. 61
31587405 2020
37
Levels of evidence supporting clinical practice guidelines on invasive aspergillosis. 61
31901113 2020
38
Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. 61
31077266 2020
39
Correction to: Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host. 61
31222102 2019
40
Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host. 61
30867554 2019
41
Severe Fever with Thrombocytopenia Syndrome Complicated with Pseudomembranous Aspergillus Tracheobronchitis in a Patient without Apparent Risk Factors for Invasive Aspergillosis. 61
31366803 2019
42
Aerosolization of Second-generation Triazoles: In Vitro Evaluation and Application in Therapy of Invasive Airway Aspergillosis. 61
31343565 2019
43
Use of Antifungals and Outcomes Among Inpatients at Risk of Invasive Aspergillosis or Mucormycosis in the USA: A Retrospective Cohort Study. 61
31598932 2019
44
Twice-Weekly Tacrolimus Can Overcome Pharmacologic Interaction and Help in the Successful Treatment of Pulmonary Aspergillosis in a Liver Transplant Recipient. 61
30373507 2019
45
Host defense mechanisms against Aspergillus fumigatus lung colonization and invasion. 61
31103956 2019
46
Galactosaminogalactan (GAG) and its multiple roles in Aspergillus pathogenesis. 61
30667338 2019
47
Fungal biofilm morphology impacts hypoxia fitness and disease progression. 61
31548684 2019
48
Respiratory specimens and the diagnostic accuracy of Aspergillus lateral flow assays (LFA-IMMY™): real-life data from a multicentre study. 61
31445208 2019
49
Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response. 61
31576498 2019
50
Fumagillin, a Mycotoxin of Aspergillus fumigatus: Biosynthesis, Biological Activities, Detection, and Applications. 61
31861936 2019

Variations for Invasive Aspergillosis

Expression for Invasive Aspergillosis

Search GEO for disease gene expression data for Invasive Aspergillosis.

Pathways for Invasive Aspergillosis

Pathways related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 TLR6 TLR5 TLR4 TLR2 TLR1 NOD2
2
Show member pathways
13.4 TLR6 TLR5 TLR4 TLR2 TLR1 IL10
3
Show member pathways
12.87 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
4
Show member pathways
12.8 TLR4 TLR2 PLG IFNG CXCL8 CXCL10
5
Show member pathways
12.67 TLR6 TLR5 TLR4 TLR2 TLR1
6
Show member pathways
12.61 TLR5 TLR4 TLR2 NOD2 IL10 IFNG
7
Show member pathways
12.57 TLR6 TLR5 TLR4 TLR2 TLR1
8 12.54 TLR6 TLR2 TLR1 IL10 IFNG CXCL10
9
Show member pathways
12.4 TLR6 TLR5 TLR4 TLR2 TLR1
10
Show member pathways
12.35 TLR5 TLR2 IFNG CXCL8 CXCL10 CSF3
11
Show member pathways
12.29 IL10 CXCL8 CXCL10 CCR6
12
Show member pathways
12.28 TLR6 TLR5 TLR4 TLR2 TLR1 CXCL8
13
Show member pathways
12.22 TLR4 TLR2 IL10 IFNG
14 12.15 TLR6 TLR5 TLR4 TLR2 TLR1 IFNG
15 12.11 TLR6 TLR4 TLR2 TLR1 NOD2 IL10
16 12.09 TLR6 TLR4 TLR2 SFTPD MBL2 CLEC7A
17
Show member pathways
12.06 TLR6 TLR5 TLR4 TLR2 TLR1
18 12 TLR4 IFNG CXCL8 CXCL10
19
Show member pathways
11.98 TLR6 TLR4 TLR2 TLR1 PLG IFNG
20
Show member pathways
11.98 TLR6 TLR5 TLR4 TLR2 TLR1 IL10
21 11.95 TLR4 TLR2 IL10 IFNG CXCL8
22 11.87 TLR4 TLR2 IFNG CXCL8
23
Show member pathways
11.82 TLR4 CXCL8 CSF3
24 11.81 TLR5 TLR4 IFNG FLNC CXCL8
25 11.77 TLR6 TLR5 TLR4 TLR2 TLR1 CLEC7A
26 11.75 IL10 IFNG CCR6
27 11.72 TLR4 IL10 CXCL8
28
Show member pathways
11.72 IFNG CXCL8 CABIN1
29 11.69 IL10 IFNG CXCL10
30 11.64 TLR5 TLR4 TLR2 CXCL8
31 11.57 IL10 CXCL8 CXCL10 CSF3
32 11.5 TLR4 TLR2 IFNG
33
Show member pathways
11.49 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
34 11.38 IL10 IFNG HBB
35 11.25 IL10 IFNG CSF3
36 11.2 TLR4 TLR2 IL10 IFNG HBB CXCL8
37 11.18 TLR2 TLR1 IFNG

GO Terms for Invasive Aspergillosis

Cellular components related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 SFTPD PLG MBL2 IL10 IFNG HBB
2 extracellular space GO:0005615 9.81 SFTPD PLG MBL2 IL10 IFNG HBB
3 phagocytic vesicle membrane GO:0030670 9.43 TLR6 TLR2 TLR1
4 cell surface GO:0009986 9.17 TLR4 TLR2 PLG NOD2 MBL2 CLEC7A
5 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 8.96 TLR2 TLR1

Biological processes related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 TLR6 TLR5 TLR4 TLR2 TLR1 IL10
2 positive regulation of cell proliferation GO:0008284 10.13 NOD2 IFNG CXCL10 CSF3 CLEC7A
3 immune system process GO:0002376 10.13 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
4 positive regulation of gene expression GO:0010628 10.11 TLR6 TLR4 TLR2 IFNG CLEC7A
5 innate immune response GO:0045087 10.06 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
6 defense response to bacterium GO:0042742 10.04 TLR6 TLR5 TLR4 SFTPD NOD2 MBL2
7 response to lipopolysaccharide GO:0032496 9.99 TLR4 TLR2 IL10 CXCL10
8 defense response GO:0006952 9.99 TLR1 NOD2 CXCL8 CXCL10
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TLR6 TLR4 TLR2 NOD2
10 cellular response to lipopolysaccharide GO:0071222 9.91 TLR5 TLR4 NOD2 IL10 CXCL8 CXCL10
11 inflammatory response GO:0006954 9.91 TLR6 TLR5 TLR4 TLR2 TLR1 IL10
12 chemokine-mediated signaling pathway GO:0070098 9.89 CXCL8 CXCL10 CCR6
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TLR4 TLR2 NOD2
14 positive regulation of interleukin-6 production GO:0032755 9.88 TLR4 TLR2 NOD2
15 positive regulation of tumor necrosis factor production GO:0032760 9.87 TLR4 TLR2 NOD2
16 positive regulation of phagocytosis GO:0050766 9.85 SFTPD MBL2 IFNG CLEC7A
17 immune response GO:0006955 9.85 TLR6 TLR4 TLR2 TLR1 IL10 IFNG
18 positive regulation of interleukin-8 production GO:0032757 9.84 TLR5 TLR4 TLR2 NOD2
19 microglial cell activation GO:0001774 9.83 TLR6 TLR2 IFNG
20 positive regulation of interleukin-12 production GO:0032735 9.83 TLR4 TLR2 IFNG
21 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.83 TLR6 TLR4 NOD2 CLEC7A
22 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.81 TLR4 TLR1 IFNG CLEC7A
23 positive regulation of interleukin-10 production GO:0032733 9.79 TLR4 TLR2 NOD2
24 leukocyte chemotaxis GO:0030595 9.79 IL10 CXCL8 CXCL10
25 positive regulation of macrophage activation GO:0043032 9.77 TLR6 TLR4 IL10
26 positive regulation of interleukin-8 secretion GO:2000484 9.77 TLR4 TLR2 TLR1
27 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.76 TLR6 TLR1 CLEC7A
28 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.76 TLR4 TLR2 NOD2 IFNG
29 response to molecule of bacterial origin GO:0002237 9.75 TLR2 IL10 CXCL8
30 cell activation GO:0001775 9.74 TLR6 TLR2 TLR1
31 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.73 TLR6 TLR4
32 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 IL10 IFNG
33 regulation of cytokine secretion GO:0050707 9.73 TLR6 TLR5 TLR2 TLR1
34 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.72 TLR4 CLEC7A
35 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.72 TLR6 TLR4
36 I-kappaB phosphorylation GO:0007252 9.72 TLR4 TLR2
37 macrophage activation GO:0042116 9.72 TLR4 TLR1
38 negative regulation of amyloid-beta clearance GO:1900222 9.72 IFNG CYP51A1
39 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.72 TLR6 TLR5 TLR4 TLR2 TLR1
40 cellular response to lipoteichoic acid GO:0071223 9.71 TLR4 TLR2
41 interleukin-1 beta secretion GO:0050702 9.71 TLR6 TLR4
42 positive regulation of NLRP3 inflammasome complex assembly GO:1900227 9.7 TLR6 TLR4
43 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.7 TLR4 CLEC7A
44 cellular response to diacyl bacterial lipopeptide GO:0071726 9.7 TLR6 TLR2
45 positive regulation of killing of cells of other organism GO:0051712 9.69 IFNG CLEC7A
46 positive regulation of oxidative stress-induced neuron death GO:1903223 9.68 TLR6 TLR4
47 toll-like receptor TLR6:TLR2 signaling pathway GO:0038124 9.68 TLR6 TLR2
48 toll-like receptor TLR1:TLR2 signaling pathway GO:0038123 9.67 TLR2 TLR1
49 positive regulation of toll-like receptor signaling pathway GO:0034123 9.67 TLR5 TLR2
50 cytokine secretion involved in immune response GO:0002374 9.67 TLR2 NOD2

Molecular functions related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 TLR6 TLR5 TLR4 TLR2 TLR1 SFTPD
2 signaling receptor binding GO:0005102 9.83 TLR6 TLR4 PLG MBL2 CXCL10
3 transmembrane signaling receptor activity GO:0004888 9.76 TLR6 TLR5 TLR4 TLR1
4 amyloid-beta binding GO:0001540 9.65 TLR6 TLR4 TLR2
5 signaling receptor activity GO:0038023 9.55 TLR6 TLR4 TLR2 TLR1 CCR6
6 lipopolysaccharide binding GO:0001530 9.5 TLR4 TLR2 SFTPD
7 signaling pattern recognition receptor activity GO:0008329 9.49 TLR2 CLEC7A
8 lipopolysaccharide receptor activity GO:0001875 9.37 TLR4 TLR2
9 cytokine activity GO:0005125 9.35 IL10 IFNG CXCL8 CXCL10 CSF3
10 Toll-like receptor 2 binding GO:0035663 9.26 TLR6 TLR1
11 lipopeptide binding GO:0071723 8.8 TLR6 TLR2 TLR1

Sources for Invasive Aspergillosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....